WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

Home・Aandelen Lijst・Compass Pathways Plc ADR

Compass Pathways Plc ADR

Gesloten

9.56 4.82

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.35

Max

9.56

Belangrijke statistieken
By Trading Economics
Inkomsten	44M -94M
Werknemers	156
EBITDA	91M -46M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+127.87% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	670M 1.3B
Vorige openingsprijs	4.74
Vorige sluitingsprijs	9.56

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

3.645 / 4.0539 Steun & Weerstand

Compass Pathways Plc ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 19:19 UTC

Acquisities, Fusies, Overnames

Intertek Group Rejects EQT's Revised Offer

24 apr 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Winsten

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Winsten

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Winsten

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Marktinformatie

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisities, Fusies, Overnames

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisities, Fusies, Overnames

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Marktinformatie

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Marktinformatie

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Winsten

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Winsten

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr 2026, 17:28 UTC

Marktinformatie

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr 2026, 17:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

24 apr 2026, 17:11 UTC

Marktinformatie

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr 2026, 17:09 UTC

Marktinformatie

Winsten

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr 2026, 17:09 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:06 UTC

Winsten

Acquisities, Fusies, Overnames

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr 2026, 16:51 UTC

Winsten

Acquisities, Fusies, Overnames

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr 2026, 16:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

24 apr 2026, 16:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 16:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

24 apr 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Compass Pathways Plc ADR Prognose

Koersdoel

By TipRanks

127.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21.83 USD 127.87%

Hoogste 70 USD

Laagste 8 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compass Pathways Plc ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Compass Pathways Plc ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.645 / 4.0539Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.